Wednesday, 6 August 2014

Lymphoblastic Lymphoma Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020

Transparency Market Research Reports incorporated a definite business overview and investigation inclines on “Lymphoblastic Lymphoma Market”. This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure. Lymphobalstic lymphoma is also known as non-hodgkin lymphoma a type of cancer that primarily affects lymphatic system. The lymphatic system comprises organs such as the thymus, bone marrow, spleen, and the lymph nodes (or lymph glands). Lymph nodes are connected by a network of tubes called lymphatic vessels that contain lymph fluid and lymphatic tissue is also found in other organs such as skin, lungs and stomach. Prevalence of lymphoblastic lymphoma is high in teenagers and children compared to adults. According to National Cancer Institute (NCI), lymphoblastic lymphoma is the third most common childhood malignancy, and lymphoblastic lymphoma accounts for approximately 7% of cancers in children younger than 20 years. In the United States, in 2013 about 800 new cases of lymphoblastic lymphoma are diagnosed each year.
Lymphoblastic lymphoma is an aggressive lymphoma. This means that it is fast-growing and needs treatment straight away with chemotherapy. The primary symptoms observed in lymphoblastic lymphoma are enlarged lymph nodes, enlarged spleen, thrombocytopenia, fatigue, dyspnea and others. The types of lymphoblastic lymphoma are overactive bladder syndrome, chlamydia, cervical cancer, polycystic ovary syndrome (PCOS), pelvic inflammatory diseases and others.
The lymphoblastic lymphoma is diagnosed by removing enlarged lymph nodes and examining with blood tests, x-rays and scans, lumbar puncture and bone marrow. The first line of treatment for lymphoblastic lymphoma consists of chemotherapy, radiotherapy, stem cell support and steroid therapy. Chemotherapy is the main treatment for lymphoblastic lymphoma usually treated more intensively than other types of lymphomas. The patients are primarily referred to a specialist centre for treatment and it is similar to the treatment for acute lymphoblastic leukaemia. The three types of chemotherapies are used against lymphoblastic lymphoma market such as induction chemotherapy, consolidation therapy and continuing therapy. The potential complications of lymphoblastic lymphoma include opportunistic infections, neutropenic fever (admit the patient), bleeding, and tumor lysis syndrome.
North America was observed to be the largest market for lymphoblastic lymphoma treatment and the major reasons behind this is the increasing prevalence of genetic diseases and advanced diagnostic facilities. In the U.S., the incidence of lymphoblastic lymphoma is roughly 3000-3500 or approximately 1 in 50,000 in 2012. While currently it has peak the incident rate of 2–5 years old, decreasing in incidence with increasing age before increasing again at around 50 years old. Lymphoblastic lymphoma is slightly more common in males than females and an increased incidence in people with a family history of autoimmune diseases, particularly autoimmune thyroid diseases (namely Graves' disease or Hashimoto's thyroiditis). Asia-Pacific were observed to be the most potential market as the developing healthcare facilities and acceptance of modern technology are enhancing the diagnostics of disease where the detection of lymphoblastic lymphoma is easily observed. The high investments were observed in the point of care sector of healthcare in the emerging markets such as India, China, Brazil, Mexico and others that are driving the market growth in these regions.
Some of the key players in this market are Novartis AG, Pfizer Inc., Sanofi SA, Jazz Pharmaceuticals plc, Bristol-Myers Squibb Company, AstraZeneca PLC, Eisai Inc., Amgen Inc. and BioCryst Pharmaceuticals, Inc. Key players involved in the research and development are National Cancer Institute, Fred Hutchinson Cancer Research Center, The University of Texas M. D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center , St. Jude Children's Research Hospital, Inc., Johann Wolfgang Goethe University Hospitals and others.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America
  • Asia Pacific
  • Europe
  • Rest of the World
This report provides comprehensive analysis of
  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.
Transparency Market Research
90 State Street,
Suite 700,
NY — 12207
United States
Tel: +1-518-618-1030
USA — Canada Toll Free 866-552-3453

Browse Market Research Blogs:


Post a Comment